Browsing items tagged “Eli Lilly | EVERSANA”

ICER’s 2020 Unsupported Price Increase Analysis Will Focus on 13 Drugs

Country: UNITED STATES | Region: NORTH AMERICA | Type: Cost Effectiveness | Keywords: #clinicalevidence #icer #prescriptiondrugs #pricechanges #priceincreases PRICENTRIC BRIEF: The Institute for Clinical and Economic Review (ICER) published its protocol for its upcoming “Unsupported Price Increase” (UPI) report in which the institute will examine significant price increases for prescription drugs and determine if new evidence is needed to support the increases ICER’s report will focus on up […]

Japan’s PMDA Evaluates Side Effects of Insulins, Cancer Drugs

Country: JAPAN | Region: ASIA & SOUTH PACIFIC | Type: Regulation | Keywords: #astrazeneca #cancer #elililly #insulin #janssen #novonordisk #pmda #sideeffects PRICENTRIC BRIEF: Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) is currently investigating new side effect risks for 15 insulins and two cancer drugs The PMDA is examining risks associated with Eli Lilly’s Humalog/Lyumjev (insulin lispro) and Novo Nordisk’s Xultophy (insulin degludec + liraglutide) and Fiasp (insulin aspart) Also under review […]